Scarica l'app Stockscreener
1.80
1.64%
-0.03
Precedente Chiudi:
$1.83
Aprire:
$1.77
Volume 24 ore:
5.76M
Relative Volume:
1.92
Capitalizzazione di mercato:
$67.36M
Reddito:
-
Utile/perdita netta:
$-57.91M
Rapporto P/E:
-1.2865
EPS:
-1.3991
Flusso di cassa netto:
$-38.14M
1 W Prestazione:
-86.61%
1M Prestazione:
-88.43%
6M Prestazione:
-85.77%
1 anno Prestazione:
-69.75%
Intervallo 1D:
$1.71
$1.87
Intervallo di 1 settimana:
$1.31
$1.92
Portata 52W:
$1.31
$19.40
Tenax Therapeutics Inc Stock (TENX) Company Profile
Nome
Tenax Therapeutics Inc
Settore
Industria
Telefono
919-855-2100
Indirizzo
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
1.80 | 64.37M | 0 | -57.91M | -38.14M | -1.3991 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-08 | Iniziato | Piper Sandler | Overweight |
| 2024-10-24 | Iniziato | Leerink Partners | Outperform |
| 2024-10-14 | Iniziato | Guggenheim | Buy |
| 2024-09-30 | Iniziato | William Blair | Outperform |
| 2017-05-18 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2014-12-16 | Iniziato | MLV & Co | Buy |
| 2014-11-18 | Iniziato | WallachBeth | Buy |
Mostra tutto
Tenax Therapeutics Inc Borsa (TENX) Ultime notizie
Tenax Therapeutics (NASDAQ:TENX) Rating Lowered to Strong Sell at Wall Street Zen - marketbeat.com
Ikarian Capital (TENX) discloses 2.9% beneficial stake in Tenax Therapeutics common stock - Stock Titan
Venrock group (TENX) discloses 1.57M-share warrant-based stake in Tenax - Stock Titan
Perceptive Advisors (TENX) reports beneficial ownership of 1.7M Tenax Therapeutics shares - Stock Titan
Tenax Therapeutics (TENX) holder BVF reports 3.11M shares, big warrant overhang - Stock Titan
Vivo Opportunity discloses 9% Tenax Therapeutics (TENX) holding via stock and warrants - Stock Titan
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX) - Business Wire
RTW Investments discloses 9.99% Tenax Therapeutics (TENX) position with 2.87M shares - Stock Titan
TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics - Morningstar
Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX) - Morningstar
Adage Capital discloses 6.81% Tenax Therapeutics (TENX) stake via stock and warrants - Stock Titan
Tenax Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
Tenax Therapeutics Inc (NASDAQ: TENX) Share Price, TENX Stock News, TENX Share Price & Updates - kalkine.ca
Tenax Therapeutics downgraded to Neutral after ... - pluang.com
Tenax Stock Plunges 89% After PH-HFpEF Trial Misses Main Goal, But Subgroup Data Offers Hope - finance.biggo.com
TENX Downgraded by Chardan Capital -- Price Target Lowered to $5.00 - GuruFocus
Tenax Therapeutics (NASDAQ:TENX) Rating Lowered to Neutral at Chardan Capital - marketbeat.com
TENX Maintained by Guggenheim -- Price Target Lowered to $4.00 - GuruFocus
TENX Downgraded by Evercore ISI Group -- Price Target Lowered to $5.00 - GuruFocus
Tenax Therapeutics (NASDAQ:TENX) Downgraded by Evercore to "In-Line" - marketbeat.com
A Quick Look at Today's Ratings for Tenax Therapeutics(TENX.US), With a Forecast Between $4 to $4 - Moomoo
Leerink Partners Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Announces Target Price $4 - Moomoo
Guggenheim cuts Tenax Therapeutics price target to $4 on trial miss - Investing.com South Africa
TENAX THERAPEUTICS INC : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING - Bitget
Evercore ISI Downgrades Tenax Therapeutics to In Line From Outperform, Adjusts PT to $5 From $39 - marketscreener.com
Tenax Therapeutics’ stock crashes on Phase III trial failure - Yahoo Finance
We're Not Very Worried About Tenax Therapeutics' (NASDAQ:TENX) Cash Burn Rate - simplywall.st
TENAX THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $4 FROM $26 - Bitget
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF PatientsSlideshow (NASDAQ:TENX) 2026-08-11 - Seeking Alpha
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case - marketbeat.com
Tenax Therapeutics (TENX) Stock Crashed: Here Is Why - top1markets.com
TENAX THERAPEUTICS INC : CANACCORD GENUITY CUTS TARGET PRICE TO $4 FROM $35 - Bitget
Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors: Johnson Fistel Investigates Potential Securities Law Violations After Phase 3 Trial Failure; Shares Plummet Nearly 90% - lincolnjournal.com
Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors: Johnson - GlobeNewswire
Tenax Therapeutics (NASDAQ:TENX) Sets New 52-Week LowHere's Why - marketbeat.com
William Blair downgrades Tenax Therapeutics stock rating on trial results By Investing.com - Investing.com UK
TENX Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
Chapel Hill drug developer's stock plunges 90% after trial setback - The Business Journals
William Blair Downgrades Tenax Therapeutics(TENX.US) to Hold Rating - Moomoo
William Blair downgrades Tenax Therapeutics stock rating on trial results - Investing.com Nigeria
Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback - Benzinga
Tenax drug trial misses mark, shares plunge 90% - Business North Carolina
Tenax, Sionna Shares Sink After Trial Failures -- WSJ - Bitget
Tenax Therapeutics shares plunged 87.2% after the company's heart drug failed to meet the primary endpoint in a late-stage study. - Bitget
Tenax Therapeutics (TENX) Shares Collapse 89% After Phase 3 Tria - GuruFocus
Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103 - Yahoo Finance
Why Did TENX Stock Crash 89% Today? - Yahoo Finance
Tenax Therapeutics (TENX) Stock Plummets 87% Amid Clinical Setba - GuruFocus
Tenax Therapeutics Inc. (TENX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Tenax Therapeutics (TENX) Stock Drops 84% After Phase 3 LEVEL Trial Misses Primary Endpoint - CoinCentral
TENX Stock Whipsaws As Traders Target Volatile Setup - timothysykes.com
Tenax Therapeutics Inc Azioni (TENX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tenax Therapeutics Inc Azioni (TENX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rich Stuart | Chief Medical Officer |
Dec 09 '25 |
Buy |
10.22 |
2,500 |
25,542 |
5,266 |
| Rich Stuart | Chief Medical Officer |
Dec 08 '25 |
Buy |
10.10 |
2,500 |
25,250 |
5,000 |
| Rich Stuart | Chief Medical Officer |
Dec 04 '25 |
Buy |
9.20 |
2,500 |
22,998 |
2,500 |
| Rich Stuart | Chief Medical Officer |
Dec 03 '25 |
Buy |
9.08 |
1,500 |
13,618 |
2,766 |
| Rich Stuart | Chief Medical Officer |
Dec 02 '25 |
Buy |
9.01 |
1,000 |
9,006 |
1,266 |
| Giordano Christopher Thomas | CEO |
Nov 18 '25 |
Buy |
7.75 |
1,612 |
12,500 |
1,612 |
| Giordano Christopher Thomas | CEO |
Nov 20 '25 |
Buy |
7.59 |
538 |
4,083 |
2,605 |
| Giordano Christopher Thomas | CEO |
Nov 19 '25 |
Buy |
7.51 |
455 |
3,417 |
2,067 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.25 |
6,000 |
43,490 |
5,000 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.34 |
2,000 |
14,674 |
2,000 |
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):